LUND, Sweden, Nov. 28, 2018 /PRNewswire/ -- Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and Buvidal® ...

Camurus, a Swedish research-based pharmaceutical company, announced that the European Commission (EC) has approved weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of ...

Phase 3 post-hoc analysis indicates less fentanyl and overall illicit opioid use for weekly/monthly buprenorphine depots versus daily standard treatment in a difficult to treat patient population LUND ...

LUND, Sweden, April 9, 2019 /PRNewswire/ -- Camurus' (NASDAQ STO: CAMX) US partner, Braeburn Inc., today announced that the company today will file an action in federal district court for the District ...

Camurus AB, a Swedish, science-led biopharmaceutical company, announced that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal prolonged release ...

- Individualized treatment of opioid dependence with weekly and monthly Buvidal ® was well-tolerated and effective, with a high (73.6%) patient retention across the 48-week study - 83.4% of ...

The full CMI on the next page has more details. If you are worried about being given this medicine, speak to your doctor, nurse practitioner or pharmacist. Buvidal contains the active ingredient ...

LUND, Sweden, Nov. 22, 2018 /PRNewswire/ -- Camurus announced today that the European Commission (EC) has approved weekly and monthly Buvidal® (prolonged release buprenorphine) for the treatment of ...

- Buvidal(R) is the first long-acting medicine approved in the EU for the treatment of opioid dependence in adults and adolescents Camurus announced today that the European Commission has granted ...

LUND, Sweden, Nov. 28, 2018 /PRNewswire/ -- Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal Weekly and Buvidal ...